Valuation: FamiCord AG

Market Cap 51.25M 58.64M 48.17M 43.96M 82.5M 5.61B 82.51M 578M 223M 2.86B 220M 215M 9.23B P/E 2026 *
294x
P/E 2027 * 49x
Enterprise Value 59.25M 67.8M 55.69M 50.82M 95.37M 6.48B 95.39M 668M 258M 3.31B 255M 249M 10.67B EV / Sales 2026 *
0.7x
EV / Sales 2027 * 0.65x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 week+3.99%
Current month-1.00%
1 month+1.21%
1 week 2.6
Extreme 2.6015
2.68
1 month 2.51
Extreme 2.506
2.76
Current year 2.51
Extreme 2.506
3.5
1 year 2.51
Extreme 2.506
3.5
3 years 2.51
Extreme 2.506
3.5
5 years 2.51
Extreme 2.506
3.5
10 years 2.51
Extreme 2.506
3.5
Manager TitleAgeSince
Chief Executive Officer 54 21/03/2022
Director of Finance/CFO 53 31/07/2024
Chief Tech/Sci/R&D Officer - 28/02/2025
Director TitleAgeSince
Chairman 62 27/06/2017
Director/Board Member - 31/12/2016
Director/Board Member 54 30/11/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.99% - - 58.64M
-0.57%-7.82%+15.93%+22.42% 111B
+2.85%+3.37%+7.58%+73.67% 94.85B
-0.92%+1.17%-1.82%+49.82% 29.37B
-4.13%-4.99%+27.11%+90.12% 25.91B
-0.09%-1.22%-10.43%-3.03% 21.2B
+0.42%+0.46%+35.04%+286.92% 21.1B
+0.76%+3.98%-7.91%+45.38% 16.37B
-0.78%-2.65%-11.13%-7.21% 11.92B
+0.76%-3.76%+40.08%+86.12% 11.72B
Average -0.17%-1.20%+10.50%+71.58% 38.2B
Weighted average by Cap. +0.27%-1.97%+11.25%+60.90%

Financials

2026 *2027 *
Net sales 85M 97.27M 79.89M 72.9M 137M 9.3B 137M 959M 370M 4.75B 365M 357M 15.31B 88.4M 101M 83.08M 75.82M 142M 9.67B 142M 997M 385M 4.94B 380M 372M 15.92B
Net income 300K 343K 282K 257K 483K 32.82M 483K 3.38M 1.31M 16.76M 1.29M 1.26M 54.03M 1M 1.14M 940K 858K 1.61M 109M 1.61M 11.28M 4.35M 55.86M 4.3M 4.2M 180M
Net Debt 8M 9.15M 7.52M 6.86M 12.88M 875M 12.88M 90.24M 34.82M 447M 34.38M 33.62M 1.44B 6M 6.87M 5.64M 5.15M 9.66M 656M 9.66M 67.68M 26.12M 335M 25.78M 25.22M 1.08B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
684
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!